期刊文献+

贝伐单抗联合培美曲塞维持治疗对晚期非鳞状非小细胞肺癌患者循环microRNA-19以及白细胞介素-27表达的影响 被引量:10

Effect of maintenance therapy with bevacizumab-pemetrexed for advanced non-squamous non-small cell lung cancer and on the levels of circulating miR-19 and interleukin-27 expression
下载PDF
导出
摘要 目的探讨贝伐单抗联合培美曲塞维持治疗晚期非鳞状非小细胞肺癌疗效及对循环microRNA(miR)-19和白细胞介素(interleukin,IL)-27表达水平的影响。方法选择2013年3月至2014年3月入住该院的经一线含铂类方案化疗获得控制的晚期非鳞状非小细胞肺癌患者45例,遵循知情同意原则分为培美曲塞组(25例)和贝伐单抗联合培美曲塞组(20例);分别观察1年内两组疗效以及患者外周血miR-19、IL-27的表达。结果培美曲塞联合贝伐单抗组和培美曲塞组的疾病控制率分别为80%和48%,总有效率分别为45%和24%,两组间疾病控制率和总有效率比较均存在统计学差异(P<0.05);培美曲塞联合贝伐单抗组外周血miR-19表达约是培美曲塞组的0.57倍,两组间相比存在统计学差异(P<0.05)。与培美曲塞组相比,培美曲塞联合贝伐单抗组外周血IL-27表达升高,两组间相比存在统计学差异(P<0.05)。结论贝伐单抗联合培美曲赛维持治疗有助于改善晚期非鳞状非小细胞肺癌的治疗效果,降低外周血miR-19、升高IL-27的表达。 Objective To investigate the effect of maintenance therapy with bevacizumab-pemetrexed for advanced non-squamous non-small cell lung cancer and on the levels of circulating microRNA( miR)-19 and interleukin ( IL)-27 expression.Methods 45 patients with advanced no-squamous non-small cell lung cancer and gotten controlled after first-line containing cisplatin chemotherapy who en-rolled into our hospital were randomized into pemetrexed group (n=25) and bevacizumab +pemetrexed group (n=20) accroding to the principle of informed consent.The curative effect of the two groups within 1 year and the expression of circulating miR-19 and IL-27 expression were observed.Results The disease control rate was 80%in bevacizumab +pemetrexed group and was 48%in peme-trexed group,the overall response rate was 45%in bevacizumab +pemetrexed group and was 24%in pemetrexed group.There have significant difference between two groups in the disease control rate and the overall response rate (P〈0.05).The levels of circulating miR-19 in bevacizumab +pemetrexed group was 0.57 fold the pemetrexed group.There has significant difference between two groups in the levels of circulating miR-19 (P〈0.05).Compared with the pemetrexed group,the levels of circulating IL-27 were increased in bevacizumab +pemetrexed group (P〈0.05).Conclusion Maintenance therapy with bevacizumab +pemetrexed for advanced non-squamous non-small cell lung cancer could improve the clinical therapy effect,reduce the levels of circulating miR-19 expression and increased circulating IL-27 expression .
出处 《安徽医药》 CAS 2015年第9期1786-1790,共5页 Anhui Medical and Pharmaceutical Journal
基金 广东省自然科学基金项目(No S2013040014341) 广东省医学科研课题(No B2013061)
关键词 非小细胞肺癌 microRNA-19 白细胞介素-27 贝伐单抗 培美曲塞 non-small cell lung cancer bevacizumab pemetrexed
  • 相关文献

参考文献24

  • 1郝捷.2012中国肿瘤登记年报[M].北京:军事医学科学出版社.2012.
  • 2Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future[J] . Transl Lung Cancer Res,2015 ,4(1) :36 -54.
  • 3Lin Q, Chen T, Lin Q, et aI. Serum miR -19 a expression correlates with worse prognosis of patients with non-small cell lung cancer[J].J Surg Oncol,2013,107(7) :767 -771.
  • 4Elinav E, Nowarski R, Thaiss CA, et aI. Inflammation-induced cancer: crosstaIk between tumours, immune cells and microorganisms[J]. Nat Rev Cancer ,2013 ,13 (11 ) : 759 -771.
  • 5叶重阳,谢家政.晚期非小细胞肺癌维持治疗的进展[J].中国临床药理学与治疗学,2013,18(10):1192-1195. 被引量:4
  • 6Barlesi F , Scherpereel A, Gorbunova V, et aI. Maintenance bevacizumab - pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmaIl-celi lung cancer: updated survivaI analysis of the AV APERL (M022089) randomized phase III triaI[J]. Ann Oncol,2014,25(5) :1044 -1052.
  • 7张玉梅,李春姗,陈逸恒.贝伐单抗联合培美曲塞治疗非小细胞肺癌临床观察[J].中华肿瘤防治杂志,2014,21(1):51-54. 被引量:15
  • 8Molina - Pinelo S,Gutierrez G,Pastor MD,et aI. MicroRNA-dependent regulation of transcription in non-small cell lung cancer[J]. PLoS One,2014 ,9(3) :e90524.
  • 9刘莎,孙国平.miRNA145作为抑癌基因在胃癌中的表达及其功能研究[J].安徽医药,2014,18(10):1817-1820. 被引量:4
  • 10鄢文,靳文,王昂,宋维舒.miR-19对肺腺癌A549细胞株迁移功能的影响[J].实用医学杂志,2014,30(13):2031-2034. 被引量:5

二级参考文献91

  • 1Hideki U,Eynav K,Nathalie S,et al.Targeting human dendriticcell subsets for improved vaccines[J].Semin Immunol,2011,23(1):21-27.
  • 2Liu LH,Wang SJ,Shan BE,et al.IL-27-mediated activation ofnatural killer cells and inflammation produced antitumor effects forhuman esophageal carcinoma cells[J].Scand J Immunol,2008,68(1):22-29.
  • 3Delgado M.Generating tolerogenic dendritic cells with neuropep-tides[J].Hum Immunol,2009,70(5):300-307.
  • 4Sanchez-Sanchez N,Riol-Blanco L,de la Rosa G,et al.Chemo-kine receptor CCR7 induces intracellular signaling that inhibitsapoptosis of mature dendritic cells[J].Blood,2004,104(3):619-625.
  • 5Skalova K,Mollova K,Michalek J.Human myeloid dendriticcells for cancer therapy:Does maturation matter?[J].Vaccine,2010,28(32):5153-5160.
  • 6Trepiakas R,Pedersen AE,Met O,et al.Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulationand increases dendritic cell function[J].Vaccine,2009,27(16):2213-2219.
  • 7Pflanz S,Hibbert L,Mattson J,et al.WSX-1 and glycoprotein130 constitute a signal transducing receptor for IL-27[J].J Immu-nol,2004,172(4):2225-2231.
  • 8Cao J,Wong CK,Yin Y,et al.Activation of human bronchialepithelial cells by inflammatory cytokines IL-27 and TNF-a:Impli-cations for immunopathophysiology of airway inflammation[J].JCell Physiol,2010,223(3):788-797.
  • 9Hirao M,Onai N,Hiroishi K,et al.CC Chemokine receptor-7 ondendritic cells induced after interaction with apoptotic tumor cells:Critical role in migration from the tumor site to draining lymphnodes[J].Cancer Res,2000,60(8):2209-2217.
  • 10Baumer D,Trauner J,Hollfelder D,et al.JAK-STAT signalling isrequired throughout telotrophic oogenesis and short-germ embryo-genesis of the beetle tribolium[J].Dev Biol,2011,350(1):169-182.

共引文献72

同被引文献52

引证文献10

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部